Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

Completed · Phase 3 · Has a placebo group

Conditions studied: Acne Vulgaris

In brief

To compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of Acne Vulgaris

Key facts

Study ID

NCT03393494

Run by

Padagis LLC

People needed

825

Starts

2017-12-13

Expected to finish

2019-01-05

Last updated by the study team

2021-11-08

Who can join

Age: 12 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed IRB approved written informed consent/assent
• 12 to 40 years of age, inclusive.
• Clinical diagnosis of facial acne vulgaris with an inflammatory lesion (papules and pustules) count of 20-50, inclusive and a non-inflammatory (open and closed comedones) lesion count of 25-100 inclusive and no more than 2 nodulocystic lesions (e.g., nodules and cysts) including those present on the nose.
• Baseline Investigator's Global Assessment Score of 3 (moderate) or 4 (severe) on a severity scale of 0 to 4.
• Females of child bearing potential (excluding women who are surgically sterilized (tubal ligation or bilateral oophorectomy or hysterectomy) or post-menopausal for at least 2 years), in addition to having a negative urine pregnancy test at Visit 1/Day1(Baseline), must be willing to use an acceptable form of birth control during the study.

You may not qualify if…

• Pregnant, breastfeeding or planning a pregnancy within the period of their study participation period.
• Presence of more than 2 facial Nodulocystic lesions.
• Presence of any other facial skin condition that, in the Investigator's opinion, might interfere with acne vulgaris diagnosis and/or evaluations
• Any uncontrolled, chronic or serious disease or medical condition that would prevent participation in a clinical trial, or, in judgment of the investigator, would put the subject at undue risk or might confound the study assessments
• Excessive facial hair that would interfere with the diagnosis or assessment of acne vulgaris.
• History of unresponsiveness to topical adapalene and/or benzoyl peroxide therapy.
• Currently using any product containing adapalene and/or benzoyl peroxide and/or belonging to the same family.
• History of hypersensitivity or allergy to adapalene, benzoyl peroxide, retinoids and/or any ingredient in the study medication.
• Use of medications known to exacerbate acne
• Start or change within 3 months (90 days) of Visit 1 and throughout the study
• Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days (1 month) of study entry and throughout the study
• Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
• Subjects who in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study.

Where it is running

• Dermatology Consultants — High Point, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.